StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences sofosbuvir intangible asset — Accumulated amortization ($M) ($M)

Form 10-Q / 10-K Note 9

QuarterlyAnnual
Latest, FY2025
8,448
Period ended Dec 31, 2025
Change on a year earlier
+9.0%
7,749 in FY2024
History
12 years
Since FY2014
Sources
12
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSofosbuvir intangible asset — Accumulated amortization ($M) ($M)Year on yearSource
FY2025Dec 31, 20258,448+9.0%Form 10-Q (filed 2026-08-06) ↗
FY2024Dec 31, 20247,749+9.9%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 20237,050+11.0%Form 10-K (filed 2025-02-28) ↗
FY2022Dec 31, 20226,350+12.4%Form 10-K (filed 2024-02-23) ↗
FY2021Dec 31, 20215,651+14.1%Form 10-K (filed 2023-02-22) ↗
FY2020Dec 31, 20204,952+16.4%Form 10-K (filed 2022-02-23) ↗
FY2019Dec 31, 20194,253+19.7%Form 10-Q (filed 2020-05-06) ↗
FY2018Dec 31, 20183,554+24.5%Form 10-Q (filed 2019-11-05) ↗
FY2017Dec 31, 20172,855+32.4%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 20162,156+48.1%Form 10-K (filed 2018-02-27) ↗
FY2015Dec 31, 20151,456+92.3%Form 10-K (filed 2017-02-27) ↗
FY2014Dec 31, 2014757–Form 10-K (filed 2016-02-24) ↗

Cite this data

StockData. (2026). Gilead Sciences Sofosbuvir intangible asset — Accumulated amortization ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_sofosbuvir_accum

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.